RYBREVANT, generically known as amivantamab, is a prescription medication used in the treatment of certain types of non-small cell lung cancer (NSCLC). Specifically, it is designed for patients whose cancer has a specific genetic mutation known as epidermal growth factor receptor (EGFR) exon 20 insertion mutations and who have previously received unsuccessful treatment. As a bispecific antibody, RYBREVANT works by targeting two different proteins that contribute to cancer growth, offering a novel approach to cancer therapy. Administered through intravenous infusion, this medication represents a significant advancement in targeted cancer treatment, providing hope for patients with this challenging condition. Its use, however, is subject to confirmation of the specific genetic mutation through FDA-approved tests, ensuring that the treatment is matched to the patient's specific cancer profile.